BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 28853218)

  • 1. Mutational status of NRAS, KRAS, and PTPN11 genes is associated with genetic/cytogenetic features in children with B-precursor acute lymphoblastic leukemia.
    Liang DC; Chen SH; Liu HC; Yang CP; Yeh TC; Jaing TH; Hung IJ; Hou JY; Lin TH; Lin CH; Shih LY
    Pediatr Blood Cancer; 2018 Feb; 65(2):. PubMed ID: 28853218
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutations of FLT3, NRAS, KRAS, and PTPN11 are frequent and possibly mutually exclusive in high hyperdiploid childhood acute lymphoblastic leukemia.
    Paulsson K; Horvat A; Strömbeck B; Nilsson F; Heldrup J; Behrendtz M; Forestier E; Andersson A; Fioretos T; Johansson B
    Genes Chromosomes Cancer; 2008 Jan; 47(1):26-33. PubMed ID: 17910045
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of mutations in FLT3, PTPN11 and RAS genes on the overall survival of pediatric B cell precursor acute lymphoblastic leukemia in Brazil.
    Barbosa TC; Andrade FG; Lopes BA; de Andrade CF; Mansur MB; Emerenciano M; Pombo-de-Oliveira MS
    Leuk Lymphoma; 2014 Jul; 55(7):1501-9. PubMed ID: 24067137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of KRAS and NRAS Gene Mutations in Arab Asian Children With Acute Leukemia: High Frequency of RAS Mutations in Acute Lymphoblastic Leukemia.
    Al-Kzayer LF; Sakashita K; Al-Jadiry MF; Al-Hadad SA; Ghali HH; Uyen le TN; Liu T; Matsuda K; Abdulkadhim JM; Al-Shujairi TA; Matti ZI; Sughayer MA; Rihani R; Madanat FF; Inoshita T; Kamata M; Koike K
    Pediatr Blood Cancer; 2015 Dec; 62(12):2157-61. PubMed ID: 26222068
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pediatric acute lymphoblastic leukemia with t(1;19)/TCF3-PBX1 in Taiwan.
    Yen HJ; Chen SH; Chang TY; Yang CP; Lin DT; Hung IJ; Lin KH; Chen JS; Hsiao CC; Chang TT; Chang TK; Peng CT; Lin MT; Jaing TH; Liu HC; Jou ST; Lu MY; Cheng CN; Sheen JM; Chiou SS; Hung GY; Wu KH; Yeh TC; Wang SC; Chen RL; Chang HH; Yang YL; Chen SH; Cheng SN; Chang YH; Chen BW; Hsieh YL; Huang FL; Ho WL; Wang JL; Chang CY; Chao YH; Lin PC; Chen YC; Liao YM; Lin TH; Shih LY; Liang DC
    Pediatr Blood Cancer; 2017 Oct; 64(10):. PubMed ID: 28436581
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characteristics of RAS pathway mutations in juvenile myelomonocytic leukaemia: a single-institution study from Korea.
    Kim HS; Lee JW; Kang D; Yu H; Kim Y; Kang H; Lee JM; Ahn A; Cho B; Kim S; Chung NG; Kim Y; Kim M
    Br J Haematol; 2021 Dec; 195(5):748-756. PubMed ID: 34590720
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tobacco Smoke and Ras Mutations Among Latino and Non-Latino Children with Acute Lymphoblastic Leukemia.
    Kaur M; de Smith AJ; Selvin S; Zhang L; Cunningham M; Kang MW; Hansen HM; Cooper RM; McKean-Cowdin R; Wiemels JL; Metayer C
    Arch Med Res; 2016 Nov; 47(8):677-683. PubMed ID: 28476195
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Juvenile myelomonocytic leukemia: who's the driver at the wheel?
    Niemeyer CM; Flotho C
    Blood; 2019 Mar; 133(10):1060-1070. PubMed ID: 30670449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Analysis of Coexisting Gene with NRAS in Acute Myeloid Leukemia].
    Sheng YP; Hua HY; Chao HY; Zhu WY; Wang ZQ; Zhang Y; Zhou Y
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Apr; 30(2):351-356. PubMed ID: 35395962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RAS and TP53 can predict survival in adults with T-cell lymphoblastic leukemia treated with hyper-CVAD.
    Sakhdari A; Thakral B; Loghavi S; Kanagal-Shamanna R; Yin CC; Zuo Z; Routbort MJ; Luthra R; Medeiros LJ; Wang SA; Patel KP; Ok CY
    Cancer Med; 2020 Feb; 9(3):849-858. PubMed ID: 31804006
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutational landscape and clinical outcome of pediatric acute myeloid leukemia with 11q23/KMT2A rearrangements.
    Yuen KY; Liu Y; Zhou YZ; Wang Y; Zhou DH; Fang JP; Xu LH
    Cancer Med; 2023 Jan; 12(2):1418-1430. PubMed ID: 35833755
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comprehensive survey of HRAS, KRAS, and NRAS mutations in proliferative thyroid lesions from an ethnically diverse population.
    Schulten HJ; Salama S; Al-Ahmadi A; Al-Mansouri Z; Mirza Z; Al-Ghamdi K; Al-Hamour OA; Huwait E; Gari M; Al-Qahtani MH; Al-Maghrabi J
    Anticancer Res; 2013 Nov; 33(11):4779-84. PubMed ID: 24222113
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer.
    Schirripa M; Cremolini C; Loupakis F; Morvillo M; Bergamo F; Zoratto F; Salvatore L; Antoniotti C; Marmorino F; Sensi E; Lupi C; Fontanini G; De Gregorio V; Giannini R; Basolo F; Masi G; Falcone A
    Int J Cancer; 2015 Jan; 136(1):83-90. PubMed ID: 24806288
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of RAS mutations and individual variation patterns among patients with metastatic colorectal cancer: A pooled analysis of randomised controlled trials.
    Peeters M; Kafatos G; Taylor A; Gastanaga VM; Oliner KS; Hechmati G; Terwey JH; van Krieken JH
    Eur J Cancer; 2015 Sep; 51(13):1704-13. PubMed ID: 26049686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic and therapeutic role of targetable lesions in B-lineage acute lymphoblastic leukemia without recurrent fusion genes.
    Messina M; Chiaretti S; Wang J; Fedullo AL; Peragine N; Gianfelici V; Piciocchi A; Brugnoletti F; Di Giacomo F; Pauselli S; Holmes AB; Puzzolo MC; Ceglie G; Apicella V; Mancini M; Te Kronnie G; Testi AM; Vitale A; Vignetti M; Guarini A; Rabadan R; Foà R
    Oncotarget; 2016 Mar; 7(12):13886-901. PubMed ID: 26883104
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toward a NOTCH1/FBXW7/RAS/PTEN-based oncogenetic risk classification of adult T-cell acute lymphoblastic leukemia: a Group for Research in Adult Acute Lymphoblastic Leukemia study.
    Trinquand A; Tanguy-Schmidt A; Ben Abdelali R; Lambert J; Beldjord K; Lengliné E; De Gunzburg N; Payet-Bornet D; Lhermitte L; Mossafa H; Lhéritier V; Bond J; Huguet F; Buzyn A; Leguay T; Cahn JY; Thomas X; Chalandon Y; Delannoy A; Bonmati C; Maury S; Nadel B; Macintyre E; Ifrah N; Dombret H; Asnafi V
    J Clin Oncol; 2013 Dec; 31(34):4333-42. PubMed ID: 24166518
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic mutational analysis of pediatric acute lymphoblastic leukemia from a single center in China using exon sequencing.
    Zhang H; Wang H; Qian X; Gao S; Xia J; Liu J; Cheng Y; Man J; Zhai X
    BMC Cancer; 2020 Mar; 20(1):211. PubMed ID: 32164600
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene mutations in the Ras pathway and the prognostic implication in Korean patients with juvenile myelomonocytic leukemia.
    Park HD; Lee SH; Sung KW; Koo HH; Jung NG; Cho B; Kim HK; Park IA; Lee KO; Ki CS; Kim SH; Yoo KH; Kim HJ
    Ann Hematol; 2012 Apr; 91(4):511-7. PubMed ID: 21901340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RAS pathway mutations as a predictive biomarker for treatment adaptation in pediatric B-cell precursor acute lymphoblastic leukemia.
    Jerchel IS; Hoogkamer AQ; Ariës IM; Steeghs EMP; Boer JM; Besselink NJM; Boeree A; van de Ven C; de Groot-Kruseman HA; de Haas V; Horstmann MA; Escherich G; Zwaan CM; Cuppen E; Koudijs MJ; Pieters R; den Boer ML
    Leukemia; 2018 Apr; 32(4):931-940. PubMed ID: 28972594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation of clinical features with the mutational status of GM-CSF signaling pathway-related genes in juvenile myelomonocytic leukemia.
    Yoshida N; Yagasaki H; Xu Y; Matsuda K; Yoshimi A; Takahashi Y; Hama A; Nishio N; Muramatsu H; Watanabe N; Matsumoto K; Kato K; Ueyama J; Inada H; Goto H; Yabe M; Kudo K; Mimaya J; Kikuchi A; Manabe A; Koike K; Kojima S
    Pediatr Res; 2009 Mar; 65(3):334-40. PubMed ID: 19047918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.